Sturge-Weber Syndrome: Clinical Manifestations, Investigations, and Treatment
Sturge-Weber syndrome (SWS) requires early neuroimaging with contrast-enhanced MRI after 1 year of age for definitive diagnosis, aggressive seizure control with antiepileptic medications, low-dose aspirin therapy, and regular ophthalmologic surveillance every 3 months during the first year to prevent vision-threatening complications.
Clinical Manifestations
Cutaneous Features
- Facial port-wine birthmark (PWB) in the head/neck region, particularly involving the forehead, temple, or eyelids 1, 2
- The location of the birthmark correlates with risk of brain and eye involvement
- Facial asymmetry and gingival hyperplasia may develop 3
Neurological Manifestations
SWS presents with a spectrum of neurological complications 1, 4:
- Seizures: Most common neurological manifestation, often drug-resistant epilepsy (DRE)
- Stroke-like episodes: Due to impaired cerebral perfusion and venous stroke risk 5
- Migraine headaches: Frequently reported
- Cognitive deficits: Including intellectual disability and developmental delays
- Motor difficulties: Related to brain involvement
Ophthalmologic Features
Eye involvement includes 6, 7:
- Glaucoma: Most common ocular complication with bimodal onset
- Diffuse choroidal hemangioma (DCH): Present in up to 87.5% when properly screened
- Ocular vascular anomalies
- Heterochromia of the iris
- Visual field defects
Other Manifestations
- Endocrine disorders (growth hormone deficiency, central hypothyroidism) 1
- Elevated episcleral venous pressure contributing to glaucoma 6
Investigations
Neuroimaging Protocol
Timing is critical: Neuroimaging before 1 year of age has low sensitivity and may underestimate involvement; imaging after 1 year is necessary to exclude brain involvement 2.
MRI with and without contrast is the gold standard 2, 4:
- Pathognomonic findings: Unilateral intracranial leptomeningeal angiomatosis (typically ipsilateral to facial birthmark) 1
- Additional findings: Leptomeningeal enhancements, cortical calcifications, brain atrophy 2
- Early detection marker: Choroid plexus (CP) thickness measurements have high sensitivity and specificity for early/incipient changes 4
Absence of pathologic findings allows for periodic observation with repeat imaging only if new clinical signs/symptoms develop 4.
Ophthalmologic Evaluation
Enhanced depth imaging spectral-domain optical coherence tomography (EDI-SDOCT) is superior to fundus photography 7:
- EDI-SDOCT demonstrates 100% sensitivity and 100% accuracy for detecting DCH
- Fundus photography has only 35.7% sensitivity and 43.8% accuracy
- Near-infrared reflectance (NIR) imaging has 21.4% sensitivity
- EDI-SDOCT enables early diagnosis even in pediatric cases with limited cooperation 7
Surveillance schedule 4:
- Every 3 months during the first year
- Yearly thereafter to monitor for glaucoma and choroidal hemangiomas
Genetic Testing
- Somatic mosaic mutation in GNAQ gene (most common) 1, 2
- Less commonly GNA11 or GNB2 mutations 4, 5
- These are postzygotic, somatic, gain-of-function variants 4
Additional Studies
- Quantitative EEG: May help identify abnormal electrical activity
- Neuropsychological evaluation: To assess cognitive function and guide interventions 3
Treatment
Neurological Management
Seizure control is paramount 1, 2:
- Aggressive antiepileptic medication therapy as first-line treatment
- Presymptomatic treatment shows promise: Low-dose aspirin and antiepileptic drugs may delay seizure onset in at-risk infants 2, 5
- Cannabidiol (CBD): Prospective trials support usefulness 5
- Surgical options for drug-resistant epilepsy:
- Limited surgical resection of epileptogenic tissue
- Hemispherectomy in severe cases 1
Stroke prevention 5:
- Low-dose aspirin: Retrospective studies suggest benefit in reducing frequency and severity of stroke-like events 5
- Vitamin D supplementation: Emerging evidence supports use 5
Dermatologic Treatment
- Pulsed dye laser using selective photo-thermolysis for port-wine birthmark 1
- Treatment timing and modalities should be individualized based on birthmark characteristics 3
Ophthalmologic Management
Glaucoma treatment 6:
- Medical management: ROCK inhibitors show good IOP control but require verification in larger populations
- Surgical intervention: Non-penetrating procedures preferred due to safety profile and lower complication rates given anatomical abnormalities
- Early detection and treatment crucial to preserve visual function 6
Emerging Therapies
Sirolimus (mTOR inhibitor) 4, 5:
- Appears safe and potentially effective for cutaneous and extra-cutaneous features
- Limited patient data; controlled clinical studies needed
- Prospective trials show promising results 5
Multidisciplinary Care Requirements
Essential team members 3:
- Dermatologist
- Neurologist
- Ophthalmologist
- Neurosurgeon (for surgical candidates)
- Maxillofacial surgeon
- Dentist (for oral cavity assessment and gingival hyperplasia)
- Neuropsychologist
- Primary care physician for coordination
Critical Pitfalls to Avoid
- Do not rely on neuroimaging before 1 year of age to exclude brain involvement—sensitivity is too low 2
- Do not use fundus photography alone for DCH screening—87.5% of cases will be missed without EDI-SDOCT 7
- Do not delay ophthalmologic surveillance—glaucoma can develop early and cause irreversible vision loss 6
- Do not assume absence of facial PWB excludes SWS—diagnosis requires at least two of three features (facial capillary malformation, leptomeningeal malformation, ocular involvement) 3
- Do not perform endoscopy in epidermolysis bullosa patients (unrelated condition mentioned in evidence but not applicable to SWS)